Dr Reddys Laboratories Ltd (RDY) shareholders
Close on Nov 17, 2026Market cap $12.34BP/E 27.1Yield 0.57%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| K. Satish Reddy Joint filing with G.V. Prasad (13.04%), G. Anuradha (11.52%) and 3 more | 113,356,510 | 13.58% | 13D (active) amendment | Sep 17, 2025 |
| Mr. G.V. Prasad : N/A | 21,762,602 | 13.04% | 13D (active) amendment | May 22, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RDY | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Robeco Institutional Asset Management B.V. | 18,021,100 | 2.16% | $261.13M | +843,218 | 0.32% |
| Morgan Stanley | 10,936,320 | 1.31% | $158.47M | +1,564,726 | 0.01% |
| BlackRock, Inc. | 10,585,742 | 1.27% | $153.39M | −1,001,385 | 0.00% |
| Royal Bank of Canada | 9,213,269 | 1.10% | $133.51M | −770,813 | 0.02% |
| Aikya Investment Management Ltd | 8,493,852 | 1.02% | $123.08M | +494,056 | 36.13% |
| Renaissance Technologies LLC | 7,347,028 | 0.88% | $106.46M | −512,700 | 0.15% |
| Dimensional Fund Advisors LP | 5,312,065 | 0.64% | $77.04M | −11,183 | 0.01% |
| State Street Corp | 4,124,686 | 0.49% | $59.77M | +98,479 | 0.00% |
| JPMorgan Chase & Co | 4,069,357 | 0.49% | $60.47M | −302,021 | 0.00% |
| Alliancebernstein L.P. | 3,730,713 | 0.45% | $51.67M | +1,188,824 | 0.02% |
| Vanguard Capital Management LLC | 3,100,911 | 0.37% | $44.93M | – | 0.00% |
| Franklin Resources Inc | 2,844,583 | 0.34% | $41.22M | −11,511 | 0.01% |
| Nuveen, LLC | 2,827,699 | 0.34% | $40.97M | New | 0.01% |
| Bnp Paribas Arbitrage, Snc | 2,649,866 | 0.32% | $38.40M | −534,105 | 0.01% |
| Acadian Asset Management LLC | 2,260,243 | 0.27% | $32.74M | −148,518 | 0.04% |
| Marshall Wace, Llp | 2,025,356 | 0.24% | $29.35M | −638,950 | 0.02% |
| Bessemer Group Inc | 1,857,221 | 0.22% | $26.91M | +33,936 | 0.04% |
| American Century Companies Inc | 1,830,883 | 0.22% | $26.53M | +169,550 | 0.01% |
| UBS Group AG | 1,658,536 | 0.20% | $24.03M | +106,228 | 0.00% |
| Schroder Investment Management Group | 1,618,404 | 0.19% | $24.05M | +1,437,165 | 0.02% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 238 | 126M | 15.1% | 31 / 75 | 97 / 37 | 13M | 8M |
| Q1 2026 | 249 | 120M | 14.4% | 41 / 102 | 66 / 26 | 25M | 6M |
| Q4 2025 | 237 | 107M | 12.8% | 41 / 84 | 74 / 24 | 8M | 14M |
| Q3 2025 | 228 | 113M | 13.5% | 26 / 85 | 76 / 39 | 13M | 18M |
| Q2 2025 | 243 | 118M | 14.1% | 36 / 108 | 60 / 32 | 24M | 16M |
| Q1 2025 | 246 | 110M | 13.2% | 35 / 60 | 115 / 33 | 9M | 18M |
| Q4 2024 | 248 | 119M | 14.2% | 37 / 92 | 87 / 17 | 12M | 13M |
| Q3 2024 | 229 | 120M | 14.4% | 31 / 97 | 58 / 21 | 17M | 11M |
| Q2 2024 | 222 | 124M | 14.8% | 25 / 91 | 70 / 31 | 14M | 18M |
| Q1 2024 | 231 | 128M | 15.4% | 29 / 93 | 74 / 20 | 18M | 12M |
| Q4 2023 | 224 | 122M | 14.6% | 38 / 83 | 66 / 25 | 24M | 11M |
| Q3 2023 | 212 | 109M | 13.1% | 33 / 88 | 60 / 14 | 18M | 12M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
43 funds held RDY in Q2 2026, 48% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of RDY | Value | % of fund | As of |
|---|---|---|---|---|---|
| AB Emerging Markets Opportunities ETF | 3,717,214 | 0.45% | $53.86M | 2.54% | Jun 30, 2026 |
| College Retirement Equities Fund - Total Global Stock Account | 2,031,281 | 0.24% | $29.43M | 0.02% | Jun 30, 2026 |
| Vanguard Emerging Markets Stock Index Fund | 1,873,980 | 0.22% | $22.21M | 0.01% | Jul 31, 2026 |
| Avantis Emerging Markets Equity ETF | 1,715,840 | 0.21% | $23.39M | 0.09% | May 31, 2026 |
| State Street(R) SPDR(R) Portfolio Emerging Markets ETF | 1,462,431 | 0.18% | $21.19M | 0.12% | Jun 30, 2026 |
| Vanguard Global Minimum Volatility Fund | 1,369,305 | 0.16% | $16.23M | 0.81% | Jul 31, 2026 |
| Emerging Markets Core Equity 2 Portfolio | 1,350,140 | 0.16% | $16.00M | 0.04% | Jul 31, 2026 |
| Vanguard Total International Stock Index Fund | 874,071 | 0.10% | $10.36M | 0.00% | Jul 31, 2026 |
| Nuveen Emerging Markets Equity Fund | 739,096 | 0.09% | $8.76M | 0.49% | Jul 31, 2026 |
| The Emerging Markets Series | 511,886 | 0.06% | $6.07M | 0.07% | Jul 31, 2026 |
| Templeton Emerging Markets Equity Fund | 489,809 | 0.06% | $7.10M | 0.26% | Jun 30, 2026 |
| SIT Emerging Markets Equity Fund | 476,702 | 0.06% | $6.91M | 0.39% | Jun 30, 2026 |
| Dimensional Emerging Markets Value Fund | 420,830 | 0.05% | $4.99M | 0.03% | Jul 31, 2026 |
| Dimensional Emerging Core Equity Market ETF | 411,183 | 0.05% | $4.87M | 0.05% | Jul 31, 2026 |
| Dimensional Emerging Markets Core Equity 2 ETF | 371,964 | 0.04% | $4.41M | 0.05% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Madhu Sundar Subramanian Munnirpallam | Global Head of Quality and PV | 35,600 | 0.00% | Apr 10, 2026 |
| Deepak Sapra | CEO - API and Services | 75,624 | 0.01% | Apr 1, 2026 |
| Sushrut Kulkarni | GLOBAL HEAD - IPDO | 70 | 0.00% | Apr 1, 2026 |
| Erez Israeli | CHIEF EXECUTIVE OFFICER | – | – | Apr 1, 2026 |
| Venkata Ramana Motupalli | CEO - Global Generics | 68,230 | 0.01% | Apr 1, 2026 |
| Patrick Rudolf Aghanian | Head - Europe Generics | 8,450 | 0.00% | Apr 1, 2026 |
| Milan Kantilal Kalawadia | CEO - North America | 47,325 | 0.01% | Apr 1, 2026 |
| Krishna Venkatesh | Global Head - IPDO | – | – | Apr 1, 2026 |
| Venkata Narasimham Mannam | Chief Financial Officer | 61,245 | 0.01% | Apr 1, 2026 |
| Srinivasa Phanimitra Bhethanabottla | Chief Information Officer | 8,712 | 0.00% | Apr 1, 2026 |
| Alpna Seth | Director | – | – | Apr 1, 2026 |
| Sanjiv Soshil Mehta | Director | – | – | Mar 27, 2026 |
| Arun Madhavan Kumar | Director | – | – | Mar 27, 2026 |
| Pranatharthi Haran Krishnan Kodumudi | Director | – | – | Mar 27, 2026 |
| Penny Chan Wan | Director | – | – | Mar 27, 2026 |
| Leo Puri | Director | – | – | Mar 27, 2026 |
| Shikha Sanjaya Sharma | Director | – | – | Mar 27, 2026 |
| G. V. Prasad | Director | 108,813,010 | 13.04% | Mar 20, 2026 |
| K. Satish Reddy | Director | 113,356,510 | 13.58% | Mar 20, 2026 |
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Dr Reddys Laboratories's stock actually held short. Settlement fails (shares not delivered on time) peaked at 302,977 shares on Sep 14, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Erez Israeli CEO | Nov 2, 2026 | 460,726 | $6.54M | Oct 29, 2026 | STOCK OPTIONS |
| Erez Israeli Officer, Director | Jul 29, 2024 | 65,500 | $5.39M | Jul 29, 2024 | SALARY/STOCK BONUS |
| Erez Israeli Officer | Oct 27, 2023 | 5,000 | $327.25K | Oct 30, 2023 | EMPLOYMENT INCOME/STOCK BONUS |
| Erez Israeli Officer, Director | Jul 27, 2023 | 197,165 | $13.20M | Jul 29, 2023 | EMPLOYMENT INCOME/STOCK BONUS |
See a number that looks wrong?